Samsung’s chip business sits at the center of the AI-driven memory crunch, yet its share price has fallen hard on currency swings and forced selling. The case is that its broad, end‑to‑end chip capabilities and strong cash pile could let it outlast the usual boom‑and‑bust cycle—if short‑term volatility doesn’t catch investors first.Read more

Samsung operates as a two-engine business made up of consumer devices such as phones, TVs, and appliances, and semiconductors, especially memory chips. Today, the investment case is mainly driven by the semiconductor segment.Read more

The Hidden Bottleneck in Drug Development: Why Charles River Acquired a Cambodian Primate Supplier On January 12, 2026, Charles River Laboratories announced that it had signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a major non-human primate (NHP) breeding and supply company. [$510M] At first glance, this transaction might appear to be a routine supply chain acquisition in the contract research organization (CRO) industry.Read more

Dear Inotiv, My name is Jong Ik Kwon, DVM , a graduate of Seoul National University College of Veterinary Medicine. Earlier in my career, I worked for Kwangdong Pharmaceutical as a Clinical Research Manager (CRM) for two years , where I gained direct experience in clinical development, regulatory processes, and pharmaceutical operations.Read more

Drug makers are spending more on early-stage research and leaning harder on outside partners, and Inotiv aims to ride that wave by expanding its testing and development services. The upside comes from smoother operations and a reputation for high animal-care standards, but shaky customer demand and a heavy debt load could still derail the story.Read more